|
Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?
The prognosis for patients with gastric cancer is poor. In western countries even patients with localized gastric or gastro-esophageal junction adenocarcinoma are faced with 5-year survival rates of...
More... |
| All times are GMT -7. The time now is 03:03 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021